Alzheimer’s disease is the most common cause of dementia, accounting for an estimated 60% to 80% of all cases. It’s far more prevalent than any other form, and understanding what sets it apart from normal aging, what drives it biologically, and what can be done about it matters whether you’re worried about your own memory or watching changes in someone you love.
Why Alzheimer’s Dominates the Numbers
Globally, around 57 million people were living with dementia as of 2021, with nearly 10 million new cases each year. Alzheimer’s disease is responsible for the majority. The next most common types, vascular dementia and Lewy body dementia, account for far smaller shares. In large population studies, vascular dementia typically represents roughly 15% to 20% of cases, while Lewy body dementia makes up about 5% to 11%, depending on the study and the population sampled.
What complicates the picture is that many people don’t have just one type. Autopsy studies examining over 2,600 older adults found that 91% had more than one type of brain pathology present, and 41% had three or more. This “mixed dementia” is especially common in the oldest age groups, which means the clean categories used in diagnosis often blur together in reality. Still, Alzheimer’s pathology is by far the most frequent contributor.
What Happens in the Brain
Two proteins drive the damage in Alzheimer’s disease. The first, called amyloid-beta, accumulates outside brain cells and forms sticky clumps known as plaques. The second, called tau, builds up inside neurons and forms tangled fibers that disrupt the cell’s internal transport system. For years, researchers debated which protein mattered more. The current understanding is that amyloid-beta acts as the trigger: it sets off a chain reaction that converts tau from a normal, functional protein into a toxic one.
Once tau turns toxic, it drives the symptoms people actually experience. Toxic tau is responsible for the synaptic dysfunction and neuron death behind memory loss and cognitive decline. There’s also a feedback loop: once tau becomes abnormal, it appears to amplify the damage caused by amyloid-beta, accelerating the disease. This interplay between the two proteins helps explain why Alzheimer’s tends to worsen progressively rather than plateau.
The damage typically starts in areas of the brain involved in forming new memories, then gradually spreads to regions responsible for language, reasoning, and eventually basic body functions. This pattern is why short-term memory problems are usually the earliest noticeable sign.
Age Is the Strongest Risk Factor
Age drives dementia risk more powerfully than any other factor. Among people in their early 90s, the incidence rate is about 12.7% per year. By ages 95 to 99, it climbs to 21.2% per year. For centenarians, the rate reaches 40.7% per year. The risk roughly doubles every 5.5 years after age 90, with no sign of leveling off even at the most advanced ages.
But age isn’t the only factor you can point to, and importantly, not all risk factors are beyond your control. A landmark 2024 report from The Lancet Commission identified 14 modifiable risk factors that collectively account for a meaningful share of dementia cases: lower education, hearing loss, high blood pressure, smoking, obesity, depression, physical inactivity, diabetes, excessive alcohol consumption, traumatic brain injury, air pollution, social isolation, untreated vision loss, and high LDL cholesterol. The last two, vision loss and high cholesterol, were added based on newly compelling evidence. Addressing even some of these can meaningfully reduce your lifetime risk.
Early Signs vs. Normal Aging
Everyone forgets things as they get older. Misplacing your car keys, struggling to recall a word that comes to you later, or blanking on an acquaintance’s name are all part of normal aging. With typical age-related changes, your overall memory, reasoning ability, and language skills stay intact. You retain old memories, accumulated knowledge, and the ability to function independently.
The warning signs of dementia look different. Getting lost in a familiar neighborhood is a red flag. So is using unusual substitute words for common objects, like calling a watch a “hand clock.” Forgetting the name of a close family member or friend, losing old memories that were once solid, and being unable to complete routine tasks you’ve done for years all suggest something beyond normal aging. The key distinction is whether the changes disrupt daily life and independence, not just whether they’re annoying.
How Alzheimer’s Is Diagnosed
Diagnosis usually starts with cognitive testing and a detailed medical history, but confirming the specific cause of dementia increasingly relies on biomarkers. PET imaging is considered the gold standard for detecting Alzheimer’s pathology in a living person. It uses specialized tracers that bind to amyloid plaques and tau tangles in brain tissue, making them visible on a scan. This is more specific than MRI, which can show brain shrinkage but can’t distinguish Alzheimer’s from other causes.
Cerebrospinal fluid analysis offers another route, measuring levels of amyloid-beta and tau proteins collected through a spinal tap. A multi-biomarker approach, combining PET imaging with fluid biomarkers, provides the most precise diagnosis. Blood-based biomarkers are in development and show promise, but haven’t yet been approved for clinical use. For many patients, especially those with mild or early symptoms, these tools can clarify the diagnosis and guide treatment decisions years earlier than was previously possible.
Treatment Options Today
For decades, the only medications available for Alzheimer’s managed symptoms without affecting the underlying disease. That changed with the approval of newer therapies that target amyloid-beta directly. The most recent, donanemab (sold as Kisunla), was approved by the FDA for adults with mild cognitive impairment or mild-stage Alzheimer’s. It’s given as an intravenous infusion every four weeks and works by clearing amyloid plaques from the brain.
These newer treatments slow cognitive decline rather than stop or reverse it, and they carry risks. The most common side effects involve brain swelling or small bleeds visible on MRI scans, along with headaches. Not everyone is a candidate, and the benefits are most meaningful when treatment starts early, before significant brain damage has occurred. This is one reason early and accurate diagnosis has become so important. Older medications that boost chemical signaling between surviving neurons are still widely used alongside newer therapies to help with day-to-day thinking and memory.
Why Mixed Pathology Matters
The high rate of overlapping brain pathologies found in autopsy studies has practical implications. If you or a family member is diagnosed with Alzheimer’s, there’s a strong chance vascular disease, Lewy body changes, or other pathologies are contributing too. This means that strategies targeting cardiovascular health, like managing blood pressure, cholesterol, and diabetes, remain important even after an Alzheimer’s diagnosis. Treating the whole picture, not just one protein, gives the brain its best chance of functioning well for as long as possible.